Johnson & Johnson (JNJ) P/FCF 30.2 | Overview

JNJ

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$594.58B

Industry

Pharmaceuticals

EPS (TTM)

$10.98

P/E (TTM)

22.18

Div & Yield

$5.20 (2.12%)

FCF Payout Ratio

64.06%

P/S (TTM)

6.31

P/B

7.29

Diluted Shares

2.44B

Ex-Dividend

2026-02-24

Next Earnings

04-14

Forward P/E

20.62

Payout Ratio

47.08%

P/FCF (TTM)

30.18

FCF Yield

3.31%

Earnings Yield

4.51%

52 Week Range

Score Card

Explore Scores Tab

3.35

Average

Johnson & Johnson has grown revenue at 6.05% over the past year, which suggests sales are increasing. Also, it has a free cash flow margin of 20.91%, which suggests the company is very profitable.

Valuation Model

Key Score

2.00

Bad

Management

4.00

Good

Growth

4.00

Good

Profitability

5.00

Very Good

Fin. Health

3.00

Average

Dividends

1.00

Very Bad

Analyst

5.00

Very Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 10:05:14

Form 13F-HR/A

Unknown Form Type

Filed on 2026-03-18 11:57:35

Form 13F-HR/A

Unknown Form Type

Filed on 2026-03-18 11:38:20

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 21:31:29

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 20:39:41

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 20:37:30

Form ARS

Unknown Form Type

Filed on 2026-03-11 06:23:05

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-03-11 06:17:23

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-03-11 06:13:23

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 16:21:53

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-02-27 14:35:13

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-23 17:20:21

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$294.00

20.0%

Avg:

$244.40

-0.3%

Low:

$171.70

-29.9%

(% change is relative to the current stock price: $245.03)

Analyst Recommendations

Go to Analyst Tab

3.78

Good

19%

Strong Buy (6)

41%

Buy (13)

41%

Hold (13)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.jnj.com/
Address
One Johnson & Johnson Plaza, New Brunswick NEW JERSEY, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=200406

The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees.

IPO Date

1944-09-25

Industry

Pharmaceuticals

Total Employees

138,200

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Pharmaceuticals

GICS Sub

Pharmaceuticals

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

JNJ - Johnson & Johnson

677

$245.03

$0.59 (0.241%)

3.35/5

Stock Unlock

Stock Profile

Score Card

Average

Insider Transactions

Market News

Form SCHEDULE 13G/A

Filed on 2026-03-26 10:05:14

Form 13F-HR/A

Filed on 2026-03-18 11:57:35

Form 13F-HR/A

Filed on 2026-03-18 11:38:20

Form 4

Filed on 2026-03-12 21:31:29

Form 4

Filed on 2026-03-12 20:39:41

Form 4

Filed on 2026-03-12 20:37:30

Form ARS

Filed on 2026-03-11 06:23:05

Form DEFA14A

Filed on 2026-03-11 06:17:23

Form DEF 14A

Filed on 2026-03-11 06:13:23

Form 4

Filed on 2026-03-03 16:21:53

Form 144

Filed on 2026-02-27 14:35:13

Form 4

Filed on 2026-02-23 17:20:21

Financials

Price Targets

20.0%

-0.3%

-29.9%

Analyst Recommendations

About

Similar Stocks